21 results on '"Tatovic, D."'
Search Results
2. Atherosclerosis and malignant diseases
- Author
-
Djordjevic, Miodrag, Tatovic, D, Babic, D, Babic, M, and Petrovic, N
- Published
- 2002
3. Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy
- Author
-
Dul, M., primary, Nikolic, T., additional, Stefanidou, M., additional, McAteer, M.A., additional, Williams, P., additional, Mous, J., additional, Roep, B.O., additional, Kochba, E., additional, Levin, Y., additional, Peakman, M., additional, Wong, F.S., additional, Dayan, C.M., additional, Tatovic, D., additional, Coulman, S.A., additional, and Birchall, J.C., additional
- Published
- 2019
- Full Text
- View/download PDF
4. Short Report:Metabolism Stimulated urine C-peptide creatinine ratio vs serumC-peptide level for monitoring of b-cell function in thefirst year after diagnosis of Type 1 diabetes
- Author
-
Tatovic, D, Luzio, S, Dunseath, G, Liu, Yuk-Fun, Alhadj Ali, M, Peakman, M, and Dayan, C M
- Abstract
Aims To determine if urine C-peptide/creatinine ratio is a useful tool for monitoring b-cell function in new-onset Type1 diabetes.Methods Data were obtained from a prospective immunomodulation study in people with Type 1 diabetes ≤ 3 monthsfrom diagnosis, with a standard mixed-meal tolerance test and measurement of urine C-peptide/creatinine ratio carriedout at 0, 3, 6, 9 and 12 months. The change in the insulin-dose-adjusted HbA1clevel was also correlated with the changein serum/urine C-peptide level during the 12-month follow-up period.Results A significant reduction in urine C-peptide/creatinine ratio, measured after a mixed-meal, was reached at9 months (-45.4%), whilst the reduction in stimulated serum C-peptide level reached significance after 3 months(-54.7%) in placebo-treated participants. Neither change in stimulated serum C-peptide nor change in urine C-peptidelevel correlated with each other, and nor did change in insulin-dose-adjusted HbA1clevel in the first 6 months, but allmeasures correlated significantly in the second half of the 12-month follow-up period.Conclusion Mixed-meal-stimulated urine C-peptide/creatinine ratio was similar to, although less sensitive than,stimulated serum C-peptide level in monitoring b-cell function during the first year after diagnosis. Because the former issignificantly less invasive, it warrants inclusion in further studies in Type 1 diabetes and may represent an attractivealternative outcome measure in cohort studies and in children.
- Published
- 2016
5. Stimulated urine C-peptide creatinine ratio vs serum C-peptide level for monitoring of β-cell function in the first year after diagnosis of Type 1 diabetes.
- Author
-
Tatovic, D., Luzio, S., Dunseath, G., Liu, Y., Alhadj Ali, M., Peakman, M., Dayan, C. M., O'Keefe, A., Stenson, R., Pell, J., Howell, A., Arif, S., Bayly, G., Thorogood, N., Green, K., Andrews, R. C., McLintock, N., Leech, N., Kyne, D., and Joseph, F.
- Subjects
- *
BLOOD testing , *C-peptide , *CONFIDENCE intervals , *CREATININE , *PEOPLE with diabetes , *GLYCOSYLATED hemoglobin , *TYPE 1 diabetes , *LONGITUDINAL method , *NONPARAMETRIC statistics , *RESEARCH funding , *STATISTICS , *URINALYSIS , *DATA analysis , *RANDOMIZED controlled trials , *REPEATED measures design , *BLIND experiment - Abstract
Aims To determine if urine C-peptide/creatinine ratio is a useful tool for monitoring β-cell function in new-onset Type 1 diabetes. Methods Data were obtained from a prospective immunomodulation study in people with Type 1 diabetes ≤ 3 months from diagnosis, with a standard mixed-meal tolerance test and measurement of urine C-peptide/creatinine ratio carried out at 0, 3, 6, 9 and 12 months. The change in the insulin-dose-adjusted HbA1c level was also correlated with the change in serum/urine C-peptide level during the 12-month follow-up period. Results A significant reduction in urine C-peptide/creatinine ratio, measured after a mixed-meal, was reached at 9 months (−45.4%), whilst the reduction in stimulated serum C-peptide level reached significance after 3 months (−54.7%) in placebo-treated participants. Neither change in stimulated serum C-peptide nor change in urine C-peptide level correlated with each other, and nor did change in insulin-dose-adjusted HbA1c level in the first 6 months, but all measures correlated significantly in the second half of the 12-month follow-up period. Conclusion Mixed-meal-stimulated urine C-peptide/creatinine ratio was similar to, although less sensitive than, stimulated serum C-peptide level in monitoring β-cell function during the first year after diagnosis. Because the former is significantly less invasive, it warrants inclusion in further studies in Type 1 diabetes and may represent an attractive alternative outcome measure in cohort studies and in children. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.
- Author
-
Tatovic D, Marwaha A, Taylor P, Hanna SJ, Carter K, Cheung WY, Luzio S, Dunseath G, Hutchings HA, Holland G, Hiles S, Fegan G, Williams E, Yang JHM, Domingo-Vila C, Pollock E, Wadud M, Ward-Hartstonge K, Marques-Jones S, Bowen-Morris J, Stenson R, Levings MK, Gregory JW, Tree TIM, and Dayan C
- Abstract
Immunotherapy targeting the autoimmune process in type 1 diabetes (T1D) can delay the loss of β-cells but needs to have minimal adverse effects to be an adjunct to insulin in the management of T1D. Ustekinumab binds to the shared p40 subunit of interleukin (IL)-12 and IL-23, targeting development of T helper 1 cells and T helper 17 cells (T
H 1 and TH 17 cells) implicated in the pathogenesis of T1D. We conducted a double-blind, randomized controlled trial of ustekinumab in 72 adolescents aged 12-18 years with recent-onset T1D. Treatment was well tolerated with no increase in adverse events. At 12 months, β-cell function, measured by stimulated C-peptide, was 49% higher in the intervention group (P = 0.02), meeting the prespecified primary outcome. Preservation of C-peptide correlated with the reduction of T helper cells co-secreting IL-17A and interferon-γ (TH 17.1 cells, P = 0.04) and, in particular, with the reduction in a subset of TH 17.1 cells co-expressing IL-2 and granulocyte-macrophage colony-stimulating factor (IL-2+ GM-CSF+ TH 17.1 cells, P = 0.04). A significant fall in β-cell-targeted (proinsulin-specific) IL-17A-secreting T cells was also seen (P = 0.0003). Although exploratory, our data suggest a role for an activated subset of TH 17.1 cells in T1D that can be targeted with minimal adverse effects to reduce C-peptide loss, which requires confirmation in a larger study. (International Standard Randomised Controlled Trial Number Registry: ISRCTN 14274380)., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
7. Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans.
- Author
-
Hanna SJ, Thayer TC, Robinson EJS, Vinh NN, Williams N, Landry LG, Andrews R, Siah QZ, Leete P, Wyatt R, McAteer MA, Nakayama M, Wong FS, Yang JHM, Tree TIM, Ludvigsson J, Dayan CM, and Tatovic D
- Subjects
- Humans, Autoantigens, Proinsulin genetics, Gold, Injections, Intradermal, Single-Cell Gene Expression Analysis, Peptides genetics, Receptors, Antigen, T-Cell genetics, Metal Nanoparticles, Diabetes Mellitus, Type 1
- Abstract
Gold nanoparticles (GNPs) have been used in the development of novel therapies as a way of delivery of both stimulatory and tolerogenic peptide cargoes. Here we report that intradermal injection of GNPs loaded with the proinsulin peptide C19-A3, in patients with type 1 diabetes, results in recruitment and retention of immune cells in the skin. These include large numbers of clonally expanded T-cells sharing the same paired T-cell receptors (TCRs) with activated phenotypes, half of which, when the TCRs were re-expressed in a cell-based system, were confirmed to be specific for either GNP or proinsulin. All the identified gold-specific clones were CD8
+ , whilst proinsulin-specific clones were both CD8+ and CD4+ . Proinsulin-specific CD8+ clones had a distinctive cytotoxic phenotype with overexpression of granulysin (GNLY) and KIR receptors. Clonally expanded antigen-specific T cells remained in situ for months to years, with a spectrum of tissue resident memory and effector memory phenotypes. As the T-cell response is divided between targeting the gold core and the antigenic cargo, this offers a route to improving resident memory T-cells formation in response to vaccines. In addition, our scRNAseq data indicate that focusing on clonally expanded skin infiltrating T-cells recruited to intradermally injected antigen is a highly efficient method to enrich and identify antigen-specific cells. This approach has the potential to be used to monitor the intradermal delivery of antigens and nanoparticles for immune modulation in humans., Competing Interests: CD has lectured for or been involved as an advisor to the following companies: Novonordisk, Sanofi-genzyme, Janssen, Servier, Lilly, Astrazeneca, Provention Bio, UCB, MSD, Vielo Bio, Avotres, Worg, Novartis. CD holds a patent jointly with Midatech plc and Provention Bio/Sanofi. DT is a Trustee for NovoNordisk UK Research Foundation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Hanna, Thayer, Robinson, Vinh, Williams, Landry, Andrews, Siah, Leete, Wyatt, McAteer, Nakayama, Wong, Yang, Tree, Ludvigsson, Dayan and Tatovic.)- Published
- 2023
- Full Text
- View/download PDF
8. What does the licensing of teplizumab mean for diabetes care?
- Author
-
Quinn LM, Swaby R, Tatovic D, Narendran P, Besser REJ, and Dayan CM
- Subjects
- Humans, Hypoglycemic Agents adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Autoantibodies, Diabetes Mellitus, Type 1 drug therapy
- Published
- 2023
- Full Text
- View/download PDF
9. Author Correction: A perspective on treating type 1 diabetes mellitus before insulin is needed.
- Author
-
Tatovic D, Narendran P, and Dayan CM
- Published
- 2023
- Full Text
- View/download PDF
10. A perspective on treating type 1 diabetes mellitus before insulin is needed.
- Author
-
Tatovic D, Narendran P, and Dayan CM
- Subjects
- Child, Adult, Humans, Insulin therapeutic use, Autoantibodies, Hypoglycemic Agents therapeutic use, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemia chemically induced
- Abstract
Type 1 diabetes mellitus (T1DM) is a progressive autoimmune disease that starts long before a clinical diagnosis is made. The American Diabetes Association recognizes three stages: stage 1 (normoglycaemic and positive for autoantibodies to β-cell antigens); stage 2 (asymptomatic with dysglycaemia); and stage 3, which is defined by glucose levels consistent with the definition of diabetes mellitus. This Perspective focuses on the management of the proportion of individuals with early stage 3 T1DM who do not immediately require insulin; a stage we propose should be termed stage 3a. To date, this period of non-insulin-dependent T1DM has been largely unrecognized. Importantly, it represents a window of opportunity for intervention, as remaining at this stage might delay the need for insulin by months or years. Extending the insulin-free period and/or avoiding unnecessary insulin therapy are important goals, as there is no risk of hypoglycaemia during this period and the adherence burden on patients of glycaemic monitoring and daily adjustments for diet and exercise is substantially reduced. Recognizing the pressing need for guidance on adequate management of children and adults with stage 3a T1DM, we present our perspective on the subject, which needs to be tested in formal and adequately powered clinical trials., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
11. Osmoadaptive GLP-1R signalling in hypothalamic neurones inhibits antidiuretic hormone synthesis and release.
- Author
-
Greenwood MP, Greenwood M, Bárez-López S, Hawkins JW, Short K, Tatovic D, and Murphy D
- Subjects
- Neurons metabolism, Vasopressins genetics, Vasopressins metabolism, Liraglutide pharmacology, Hypothalamus metabolism
- Abstract
Objectives: The excessive release of the antidiuretic hormone vasopressin is implicated in many diseases including cardiovascular disease, diabetes, obesity, and metabolic syndrome. Once thought to be elevated as a consequence of diseases, data now supports a more causative role. We have previously identified CREB3L1 as a transcription factor that co-ordinates vasopressin synthesis and release in the hypothalamus. The objective here was to identify mechanisms orchestrated by CREB3L1 that co-ordinate vasopressin release., Methods: We mined Creb3l1 knockdown SON RNA-seq data to identify downstream target genes. We proceeded to investigate the expression of these genes and associated pathways in the supraoptic nucleus of the hypothalamus in response to physiological and pharmacological stimulation. We used viruses to selectively knockdown gene expression in the supraoptic nucleus and assessed physiological and metabolic parameters. We adopted a phosphoproteomics strategy to investigate mechanisms that facilitate hormone release by the pituitary gland., Results: We discovered glucagon like peptide 1 receptor (Glp1r) as a downstream target gene and found increased expression in stimulated vasopressin neurones. Selective knockdown of supraoptic nucleus Glp1rs resulted in decreased food intake and body weight. Treatment with GLP-1R agonist liraglutide decreased vasopressin synthesis and release. Quantitative phosphoproteomics of the pituitary neurointermediate lobe revealed that liraglutide initiates hyperphosphorylation of presynapse active zone proteins that control vasopressin exocytosis., Conclusion: In summary, we show that GLP-1R signalling inhibits the vasopressin system. Our data advises that hydration status may influence the pharmacodynamics of GLP-1R agonists so should be considered in current therapeutic strategies., (Copyright © 2023 The Authors. Published by Elsevier GmbH.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
12. Diagnosing Type 1 diabetes in adults: Guidance from the UK T1D Immunotherapy consortium.
- Author
-
Tatovic D, Jones AG, Evans C, Long AE, Gillespie K, Besser REJ, Leslie RD, and Dayan CM
- Subjects
- Adult, Genetic Predisposition to Disease, Humans, Immunotherapy, United Kingdom epidemiology, Diabetes Mellitus, Type 1 diagnosis, Diabetes Mellitus, Type 1 therapy, Diabetes Mellitus, Type 2
- Published
- 2022
- Full Text
- View/download PDF
13. Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes.
- Author
-
Tatovic D and Dayan CM
- Subjects
- Humans, Hypoglycemic Agents pharmacology, Diabetes Mellitus, Type 1 therapy, Immunotherapy methods, Insulin pharmacokinetics, Insulin-Secreting Cells metabolism
- Abstract
For almost a hundred years, the management of Type 1 diabetes has not advanced beyond insulin replacement. However, insulin does not provide satisfactory glycaemic control in the majority of individuals and there remains a major unmet need for novel treatments for Type 1 diabetes. Immunomodulation to preserve beta-cell function offers the prospect of making treatment with insulin easier and/or preventing the need for insulin, particularly when it comes to novel low-risk immunotherapies. Led by the concept that the best insulin-producing cell is a patient's own beta-cell, the Type 1 diabetes scientific community has a challenging task ahead-to fundamentally change the management of this devastating disease by using low-risk immunotherapy to preserve endogenous beta-cell function and make metabolic control substantially easier. In that way, insulin and/or beta-cell replacement (stem cell or transplantation) should in the future be considered rescue therapies reserved for delayed presentations., (© 2021 Diabetes UK.)
- Published
- 2021
- Full Text
- View/download PDF
14. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol.
- Author
-
Gregory JW, Carter K, Cheung WY, Holland G, Bowen-Morris J, Luzio S, Dunseath G, Tree T, Yang JHM, Marwaha A, Ali MA, Bashir N, Hutchings HA, Fegan GW, Stenson R, Hiles S, Marques-Jones S, Brown A, Tatovic D, and Dayan C
- Subjects
- Adolescent, C-Peptide, Clinical Trials, Phase II as Topic, Double-Blind Method, Humans, Insulin, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Diabetes Mellitus, Type 1 drug therapy, Ustekinumab therapeutic use
- Abstract
Introduction: Most individuals newly diagnosed with type 1 diabetes (T1D) have 10%-20% of beta-cell function remaining at the time of diagnosis. Preservation of residual beta-cell function at diagnosis may improve glycaemic control and reduce longer-term complications.Immunotherapy has the potential to preserve endogenous beta-cell function and thereby improve metabolic control even in poorly compliant individuals. We propose to test ustekinumab (STELARA), a targeted and well-tolerated therapy that may halt T-cell and cytokine-mediated destruction of beta-cells in the pancreas at the time of diagnosis., Methods and Analysis: This is a double-blind phase II study to assess the safety and efficacy of ustekinumab in 72 children and adolescents aged 12-18 with new-onset T1D.Participants should have evidence of residual functioning beta-cells (serum C-peptide level >0.2nmol/L in the mixed-meal tolerance test (MMTT) and be positive for at least one islet autoantibody (GAD, IA-2, ZnT8) to be eligible.Participants will be given ustekinumab/placebo subcutaneously at weeks 0, 4 and 12, 20, 28, 36 and 44 in a dose depending on the body weight and will be followed for 12 months after dose 1.MMTTs will be used to measure the efficacy of ustekinumab for preserving C-peptide area under the curve at week 52 compared with placebo. Secondary objectives include further investigations into the efficacy and safety of ustekinumab, patient and parent questionnaires, alternative methods for measuring insulin production and exploratory mechanistic work., Ethics and Dissemination: This trial received research ethics approval from the Wales Research Ethics Committee 3 in September 2018 and began recruiting in December 2018.The results will be disseminated using highly accessed, peer-reviewed medical journals and presented at conferences., Trial Registration Number: ISRCTN14274380., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
15. Insights From Single Cell RNA Sequencing Into the Immunology of Type 1 Diabetes- Cell Phenotypes and Antigen Specificity.
- Author
-
Hanna SJ, Tatovic D, Thayer TC, and Dayan CM
- Subjects
- Animals, Antigens immunology, Biomarkers, Disease Progression, Humans, Phenotype, Receptors, Antigen, B-Cell immunology, Receptors, Antigen, T-Cell immunology, Sequence Analysis, RNA, Single-Cell Analysis, Diabetes Mellitus, Type 1 genetics, Diabetes Mellitus, Type 1 immunology
- Abstract
In the past few years, huge advances have been made in techniques to analyse cells at an individual level using RNA sequencing, and many of these have precipitated exciting discoveries in the immunology of type 1 diabetes (T1D). This review will cover the first papers to use scRNAseq to characterise human lymphocyte phenotypes in T1D in the peripheral blood, pancreatic lymph nodes and islets. These have revealed specific genes such as IL-32 that are differentially expressed in islet -specific T cells in T1D. scRNAseq has also revealed wider gene expression patterns that are involved in T1D and can predict its development even predating autoantibody production. Single cell sequencing of TCRs has revealed V genes and CDR3 motifs that are commonly used to target islet autoantigens, although truly public TCRs remain elusive. Little is known about BCR repertoires in T1D, but scRNAseq approaches have revealed that insulin binding BCRs commonly use specific J genes, share motifs between donors and frequently demonstrate poly-reactivity. This review will also summarise new developments in scRNAseq technology, the insights they have given into other diseases and how they could be leveraged to advance research in the type 1 diabetes field to identify novel biomarkers and targets for immunotherapy., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Hanna, Tatovic, Thayer and Dayan.)
- Published
- 2021
- Full Text
- View/download PDF
16. Phenotypic Analysis of Human Lymph Nodes in Subjects With New-Onset Type 1 Diabetes and Healthy Individuals by Flow Cytometry.
- Author
-
Yang JHM, Khatri L, Mickunas M, Williams E, Tatovic D, Alhadj Ali M, Young P, Moyle P, Sahni V, Wang R, Kaur R, Tannahill GM, Beaton AR, Gerlag DM, Savage COS, Napolitano Rosen A, Waldron-Lynch F, Dayan CM, and Tree TIM
- Subjects
- Adult, Diabetes Mellitus, Type 1 pathology, Female, Humans, Lymph Nodes pathology, Lymphocytes pathology, Male, Diabetes Mellitus, Type 1 immunology, Flow Cytometry, Lymph Nodes immunology, Lymphocytes immunology
- Abstract
Background: Ultrasound guided sampling of human lymph node (LN) combined with advanced flow cytometry allows phenotypic analysis of multiple immune cell subsets. These may provide insights into immune processes and responses to immunotherapies not apparent from analysis of the blood. Methods: Ultrasound guided inguinal LN samples were obtained by both fine needle aspiration (FNA) and core needle biopsy in 10 adults within 8 weeks of diagnosis of type 1 diabetes (T1D) and 12 age-matched healthy controls at two study centers. Peripheral blood mononuclear cells (PBMC) were obtained on the same occasion. Samples were transported same day to the central laboratory and analyzed by multicolour flow cytometry. Results: LN sampling was well-tolerated and yielded sufficient cells for analysis in 95% of cases. We confirmed the segregation of CD69
+ cells into LN and the predominance of CD8+ Temra cells in blood previously reported. In addition, we demonstrated clear enrichment of CD8+ naïve, FOXP3+ Treg, class-switched B cells, CD56bright NK cells and plasmacytoid dendritic cells (DC) in LNs as well as CD4+ T cells of the Th2 phenotype and those expressing Helios and Ki67. Conventional NK cells were virtually absent from LNs as were Th22 and Th1Th17 cells. Paired correlation analysis of blood and LN in the same individuals indicated that for many cell subsets, especially those associated with activation: such as CD25+ and proliferating (Ki67+ ) T cells, activated follicular helper T cells and class-switched B cells, levels in the LN compartment could not be predicted by analysis of blood. We also observed an increase in Th1-like Treg and less proliferating (Ki67+ ) CD4+ T cells in LN from T1D compared to control LNs, changes which were not reflected in the blood. Conclusions: LN sampling in humans is well-tolerated. We provide the first detailed "roadmap" comparing immune subsets in LN vs. blood emphasizing a role for differentiated effector T cells in the blood and T cell regulation, B cell activation and memory in the LN. For many subsets, frequencies in blood, did not correlate with LN, suggesting that LN sampling would be valuable for monitoring immuno-therapies where these subsets may be impacted., (Copyright © 2019 Yang, Khatri, Mickunas, Williams, Tatovic, Alhadj Ali, Young, Moyle, Sahni, Wang, Kaur, Tannahill, Beaton, Gerlag, Savage, Napolitano Rosen, Waldron-Lynch, Dayan and Tree.)- Published
- 2019
- Full Text
- View/download PDF
17. Changing the landscape for type 1 diabetes: the first step to prevention.
- Author
-
Dayan CM, Korah M, Tatovic D, Bundy BN, and Herold KC
- Subjects
- Antibodies, Monoclonal, Humanized therapeutic use, Diabetes Mellitus, Type 1 etiology, Diabetes Mellitus, Type 1 immunology, Humans, Diabetes Mellitus, Type 1 prevention & control
- Abstract
Over several decades, studies have described the progression of autoimmune diabetes, from the first appearance of autoantibodies until, and after, the diagnosis of clinical disease with hyperglycaemia and insulin dependence. Despite the improved management of type 1 diabetes with exogenous insulin, most patients do not meet clinical glycaemic goals, and diabetes remains an important medical problem that affects children and adults. Clinical and preclinical studies have suggested strategies to prevent the diagnosis of type 1 diabetes in people at risk, but the outcomes of previous clinical trials have not met their primary endpoints of disease prevention or delay. The results from the TN-10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease. This Series paper discusses how this clinical achievement raises new questions about for whom, and when, immunological strategies might be developed to prevent type 1 diabetes, and how to achieve this goal., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
18. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes.
- Author
-
Alhadj Ali M, Liu YF, Arif S, Tatovic D, Shariff H, Gibson VB, Yusuf N, Baptista R, Eichmann M, Petrov N, Heck S, Yang JHM, Tree TIM, Pujol-Autonell I, Yeo L, Baumard L, Stenson R, Howell A, Clark A, Boult Z, Powrie J, Adams L, Wong FS, Luzio S, Dunseath G, Green K, O'Keefe A, Bayly G, Thorogood N, Andrews R, Leech N, Joseph F, Nair S, Seal S, Cheung H, Beam C, Hills R, Peakman M, and Dayan CM
- Subjects
- Adolescent, Adult, Autoantibodies immunology, Autoantigens immunology, C-Peptide metabolism, Diabetes Mellitus, Type 1 metabolism, Double-Blind Method, Female, Humans, Immunophenotyping, Male, Middle Aged, T-Lymphocytes, Regulatory metabolism, Young Adult, Diabetes Mellitus, Type 1 therapy, Immunotherapy methods, Peptides therapeutic use, Proinsulin therapeutic use
- Abstract
Immunotherapy using short immunogenic peptides of disease-related autoantigens restores immune tolerance in preclinical disease models. We studied safety and mechanistic effects of injecting human leukocyte antigen-DR4( DRB1*0401 )-restricted immunodominant proinsulin peptide intradermally every 2 or 4 weeks for 6 months in newly diagnosed type 1 diabetes patients. Treatment was well tolerated with no systemic or local hypersensitivity. Placebo subjects showed a significant decline in stimulated C-peptide (measuring insulin reserve) at 3, 6, 9, and 12 months versus baseline, whereas no significant change was seen in the 4-weekly peptide group at these time points or the 2-weekly group at 3, 6, and 9 months. The placebo group's daily insulin use increased by 50% over 12 months but remained unchanged in the intervention groups. C-peptide retention in treated subjects was associated with proinsulin-stimulated interleukin-10 production, increased FoxP3 expression by regulatory T cells, low baseline levels of activated β cell-specific CD8 T cells, and favorable β cell stress markers (proinsulin/C-peptide ratio). Thus, proinsulin peptide immunotherapy is safe, does not accelerate decline in β cell function, and is associated with antigen-specific and nonspecific immune modulation., (Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
- Published
- 2017
- Full Text
- View/download PDF
19. Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes.
- Author
-
Zhao X, Birchall JC, Coulman SA, Tatovic D, Singh RK, Wen L, Wong FS, Dayan CM, and Hanna SJ
- Subjects
- Administration, Topical, Adult, Aged, Aged, 80 and over, Animals, Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents therapeutic use, Antigen Presentation drug effects, Autoantigens therapeutic use, Betamethasone administration & dosage, Betamethasone therapeutic use, Chromogranin A therapeutic use, Diabetes Mellitus, Type 1 immunology, Female, Humans, Mice, Transgenic, Microinjections, Middle Aged, Needles, Peptide Fragments therapeutic use, Skin metabolism, T-Lymphocytes drug effects, T-Lymphocytes immunology, Young Adult, Autoantigens administration & dosage, Chromogranin A administration & dosage, Diabetes Mellitus, Type 1 therapy, Immunotherapy methods, Peptide Fragments administration & dosage
- Abstract
Antigen specific immunotherapy mediated via the sustained generation of regulatory T cells arguably represents the ideal therapeutic approach to preventing beta cell destruction in type 1 diabetes. However, there is a need to enhance the efficacy of this approach to achieve disease modification in man. Previous studies suggest that prolonged expression of self-antigen in skin in a non-inflammatory context is beneficial for tolerance induction. We therefore sought to develop a dry-coated microneedle (MN) delivery system and combine it with topical steroid to minimise local inflammation and promote prolonged antigen presentation in the skin. Here we show that a combination of surface-modified MNs coated with appropriate solvent systems can deliver therapeutically relevant quantities of peptide to mouse and human skin even with hydrophobic peptides. Compared to conventional "wet" intradermal (ID) administration, "dry" peptide delivered via MNs was retained for longer in the skin and whilst topical hydration of the skin with vehicle or steroid accelerated loss of ID-delivered peptide from the skin, MN delivery of peptide was unaffected. Furthermore, MN delivery resulted in enhanced presentation of antigen to T cells in skin draining lymph nodes (LNs) both 3 and 10days after administration. Repeated administration of islet antigen peptide via MN was effective at reducing antigen-specific T cell proliferation in the pancreatic LN, although topical steroid therapy did not enhance this. Taken together, these data show auto-antigenic peptide delivery into skin using coated MNs results in prolonged retention and enhanced antigen presentation compared to conventional ID delivery and this approach may have potential in individuals identified as being at a high risk of developing type 1 diabetes and other autoimmune diseases., (Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
20. Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin.
- Author
-
Ali MA, Thrower SL, Hanna SJ, Coulman SA, Birchall JC, Wong FS, Dayan CM, and Tatovic D
- Subjects
- Administration, Topical, Adult, Aged, Aged, 80 and over, Autoimmune Diseases drug therapy, Autoimmune Diseases immunology, Betamethasone administration & dosage, Betamethasone analogs & derivatives, Cytokines genetics, Cytokines metabolism, Female, Humans, Immunosuppression Therapy methods, Immunotherapy methods, In Vitro Techniques, Lymphocyte Culture Test, Mixed, Middle Aged, RNA, Messenger genetics, RNA, Messenger metabolism, Young Adult, Adrenal Cortex Hormones administration & dosage, Immune Tolerance drug effects, Langerhans Cells drug effects, Langerhans Cells immunology
- Abstract
We have investigated the efficacy of conditioning skin Langerhans cells (LCs) with agents to promote tolerance and reduce inflammation, with the goal of improving the outcomes of antigen-specific immunotherapy. Topical treatments were assessed ex vivo, using excised human breast skin maintained in organ bath cultures, and in vivo in healthy volunteers by analysing skin biopsies and epidermal blister roof samples. Following topical treatment with a corticosteroid, tumour necrosis factor-α levels were reduced in skin biopsy studies and blister fluid samples. Blister fluid concentrations of monocyte chemoattractant protein-1, macrophage inflammatory proteins -1α and 1β and interferon-γ inducible protein-10 were also reduced, while preserving levels of interleukin-1α (IL-1α), IL-6, IL-8 and IL-10. Steroid pre-treatment of the skin reduced the ability of LCs to induce proliferation, while supernatants showed an increase in the IL-10/interferon-γ ratio. Phenotypic changes following topical steroid treatment were also observed, including reduced expression of CD83 and CD86 in blister-derived LCs, but preservation of the tolerogenic signalling molecules immunoglobulin-like transcript 3 and programmed death-1. Reduced expression of HLA-DR, CD80 and CD86 were also apparent in LCs derived from excised human skin. Topical therapy with a vitamin D analogue (calcipotriol) and steroid, calcipotriol alone or vitamin A elicited no significant changes in the parameters studied. These experiments suggest that pre-conditioning the skin with topical corticosteroid can modulate LCs by blunting their pro-inflammatory signals and potentially enhancing tolerance. We suggest that such modulation before antigen-specific immunotherapy might provide an inexpensive and safe adjunct to current approaches to treat autoimmune diseases., (© 2015 The Authors. Immunology published by John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
21. Fine-Needle Aspiration Biopsy of the Lymph Node: A Novel Tool for the Monitoring of Immune Responses after Skin Antigen Delivery.
- Author
-
Tatovic D, Young P, Kochba E, Levin Y, Wong FS, and Dayan CM
- Subjects
- Adolescent, Adult, Antigens, CD immunology, Antigens, Differentiation, T-Lymphocyte immunology, Antigens, Viral administration & dosage, Biopsy, Fine-Needle instrumentation, Cell Movement, Enzyme-Linked Immunospot Assay, Female, Humans, Immunologic Memory, Immunophenotyping, Injections, Intradermal, Interferon-gamma biosynthesis, Lectins, C-Type immunology, Leukocytes, Mononuclear cytology, Leukocytes, Mononuclear drug effects, Lymph Nodes cytology, Lymph Nodes drug effects, Lymphocyte Activation, Male, Middle Aged, Skin drug effects, Skin immunology, T-Lymphocytes cytology, T-Lymphocytes drug effects, Tetanus Toxoid administration & dosage, Tuberculin administration & dosage, Biopsy, Fine-Needle methods, Leukocytes, Mononuclear immunology, Lymph Nodes immunology, T-Lymphocytes immunology
- Abstract
Assessment of immune responses in lymph nodes (LNs) is routine in animals, but rarely done in humans. We have applied minimally invasive ultrasound-guided fine-needle aspiration of the LN to a before-and-after study of the immune response to intradermally delivered Ag in healthy volunteers (n = 25). By comparison with PBMCs from the same individual, LN cells (LNCs) were characterized by reduced numbers of effector memory cells, especially CD8(+) TEMRA cells (3.37 ± 1.93 in LNCs versus 22.53 ± 7.65 in PBMCs; p = 0.01) and a marked increased in CD69 expression (27.67 ± 7.49 versus 3.49 ± 2.62%, LNCs and PBMCs, respectively; p < 0.0001). At baseline, there was a striking absence of IFN-γ ELISPOT responses to recall Ags (purified protein derivative, Tetanus toxoid, or flu/EBV/CMV viral mix) in LN, despite strong responses in the peripheral blood. However, 48 h after tuberculin purified protein derivative administration in the ipsilateral forearm resulting in a positive skin reaction, a clear increase in IFN-γ ELISPOT counts was seen in the draining LN but not in PBMCs. This response was lost by 5 d. These data suggest that the low levels of effector memory cells in the LN may explain the low background of baseline ELISPOT responses in LNs as compared with PBMCs, and the appearance of a response after 48 h is likely to represent migration of effector memory cells from the skin to the LN. Hence, it appears that the combination of intradermal Ag administration and draining LN sampling can be used as a sensitive method to probe the effector memory T cell repertoire in the skin., (Copyright © 2015 by The American Association of Immunologists, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.